Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
14:35:48 EDT Tue 25 Mar 2025
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:NRBO - NEUROBO PHARMACEUTICALS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
NRBO - QDEFUNCT2.36    6.7499  2.08Nov 27Nov 1815 min RT 2¢

Recent Trades - All 0 today
Time ETExPriceChangeVolume
     
     
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-11-18 08:01U:NRBONews ReleaseNeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic Diseases
2024-11-15 08:35U:NRBONews ReleaseLife Sciences Investor Forum: Presentations Now Available for Online Viewing
2024-11-13 08:01U:NRBONews ReleaseNeuroBo Pharmaceuticals to Participate in Investor Conferences in November
2024-11-12 08:35U:NRBONews ReleaseLife Sciences Investor Forum Agenda Announced for November 14th
2024-11-07 08:01U:NRBONews ReleaseNeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update
2024-11-04 08:01U:NRBONews ReleaseNeuroBo Pharmaceuticals Completes Last Patient Last Visit in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
2024-10-01 08:01U:NRBONews ReleaseNeuroBo Pharmaceuticals to Participate in Investor Conferences in October
2024-09-30 08:01U:NRBONews ReleaseNeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
2024-09-03 08:01U:NRBONews ReleaseNeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
2024-08-14 08:01U:NRBONews ReleaseNeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Update
2024-08-13 08:01U:NRBONews ReleaseNeuroBo Pharmaceuticals Completes Enrollment of the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
2024-08-06 08:01U:NRBONews ReleaseNeuroBo Pharmaceuticals Announces Joint Research Agreement, Together with Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 for the Treatment of Obesity
2024-07-30 08:01U:NRBONews ReleaseNeuroBo Pharmaceuticals Announces Exclusive License Agreement with MThera Pharma for NB-01
2024-07-11 08:01U:NRBONews ReleaseNeuroBo Pharmaceuticals to Present at the Emerging Growth Conference in July
2024-06-26 09:06U:NRBONews ReleaseNeuroBo Pharmaceuticals Doses First Patient in the MAD Part 2 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
2024-06-25 17:07U:NRBONews ReleaseNeuroBo Pharmaceuticals Announces the Closing of up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
2024-06-24 08:01U:NRBONews ReleaseNeuroBo Pharmaceuticals Announces up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
2024-06-22 08:01U:NRBONews ReleaseNeuroBo Pharmaceuticals' DA-1726 Demonstrated Superiority in Weight Loss, Retention of Lean Body Mass, and Lipid-Lowering Effects Compared to Survodutide, in Pre-Clinical Models
2024-05-22 08:01U:NRBONews ReleaseNeuroBo Pharmaceuticals' DA-1241 in Combination with Semaglutide Improves Liver Fibrosis and Demonstrates Additive Hepatoprotective Effects in Pre-Clinical MASH Models Compared to Either Treatment, Alone
2024-05-09 08:01U:NRBONews ReleaseNeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update